GeneDx (WGS) announced new data from the SeqFirst study, conducted with Seattle Children’s, supporting rapid exome and genome sequencing as a first-tier test for non-critical pediatric inpatients. Published in The Journal of Pediatrics, the analysis showed rapid genome testing dropped the average time to a precise genetic diagnosis from almost ten months to 13 days. The diagnostic yield remained high at over 42%, comparable to critical care settings. The study supports broader adoption to improve patient outcomes and lower healthcare costs.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- GeneDx says AAP recommends exome, genome sequencing as tests for children
- AAP guidance ‘another reason to believe’ in GeneDx, says Craig-Hallum
- GeneDx Holdings: Navigating Market Opportunities and Delayed Financial Impact Amid AAP Testing Guidelines Update
- Galatea Bio, Fabric Genomics partner on genetic testing for common diseases
- GeneDx Holdings Approves Key Proposals at Annual Meeting